

# ESMO-MCBS:H

ESMO-Magnitude of Clinical Benefit Scale  
for Haematological Malignancies

## EVALUATION FORM 2A

For therapies that are not likely to be curative with primary endpoint of OS

Name of study:	<input type="text"/>		
Study medicine:	<input type="text"/>	Indication:	<input type="text"/>
First author:	<input type="text"/>	Year:	<input type="text"/>
		Journal:	<input type="text"/>
Name of evaluator:	<input type="text"/>		

If median OS with the standard treatment is <12 months

<b>GRADE 4</b>	HR $\leq 0.65$ <u>AND</u> gain $\geq 3$ months	<input type="radio"/>
	Increase in 2-year survival $\geq 10\%$ (if $>20\%$ of patients have reached 2-year OS)	<input type="radio"/>
<b>GRADE 3</b>	HR $\leq 0.65$ <u>AND</u> gain $\geq 2$ - $<3$ months	<input type="radio"/>
<b>GRADE 2</b>	HR $\leq 0.65$ <u>AND</u> gain $\geq 1.5$ - $<2$ months	<input type="radio"/>
	HR $>0.65$ - $0.70$ <u>AND</u> gain $\geq 1.5$ months	<input type="radio"/>
<b>GRADE 1</b>	HR $>0.70$ <u>OR</u> gain $<1.5$ months	<input type="radio"/>

Mark with  $\checkmark$  if relevant

<b>Preliminary magnitude of clinical benefit score</b>	<b>4</b> <input type="checkbox"/>	<b>3</b> <input type="checkbox"/>	<b>2</b> <input type="checkbox"/>	<b>1</b> <input type="checkbox"/>
--	-----------------------------------	-----------------------------------	-----------------------------------	-----------------------------------

# ESMO-MCBS:H

ESMO-Magnitude of Clinical Benefit Scale  
for Haematological Malignancies

## Quality of Life/Grade 3-4 toxicities assessment

Was QoL evaluated as secondary outcome?

Is QoL improved according to the ESMO-MCBS QoL checklist?

Are there statistically significantly less grade 3-4 toxicities impacting on daily well-being?\*

\*This does not include alopecia, myelosuppression, but rather chronic nausea, diarrhoea, fatigue, etc.

Mark with ✓ if relevant

## Adjustments

01. Upgrade 1 level if improved QoL and/or fewer grade 3-4 toxicities impacting daily well-being are shown
02. If there is a long-term plateau in the survival curve, and OS advantage continues to be observed at 5-year, also score according to form 1a (treatments with curative potential) and present both scores i.e. A/4

<b>Final adjusted magnitude of clinical benefit score</b>	<b>5</b> <input type="checkbox"/>	<b>4</b> <input type="checkbox"/>	<b>3</b> <input type="checkbox"/>	<b>2</b> <input type="checkbox"/>	<b>1</b> <input type="checkbox"/>
---	-----------------------------------	-----------------------------------	-----------------------------------	-----------------------------------	-----------------------------------

Non-curative setting grading 5 and 4 indicate a substantial magnitude of clinical benefit